The J6JFH1 strain of hepatitis C virus infects human B-cells with low replication efficacy

Viral Immunology

Volumn 27, Issue 6, 2014, Pages 285-294

  Nakai, Masato ^a   Seya, Tsukasa ^a   Matsumoto, Misako ^a   Shimotohno, Kunitada ^b   Sakamoto, Naoya ^a   Aly, Hussein H ^a,c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; VIRUS RNA;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; EXOSOME; GENOME; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VOLUNTEER; CELL LINE; CLASSIFICATION; HEPACIVIRUS; ISOLATION AND PURIFICATION; LIVER CELL; PHYSIOLOGY; TIME; VIROLOGY;

B-LYMPHOCYTES; CELL LINE; HEPACIVIRUS; HEPATOCYTES; HUMANS; RNA, VIRAL; TIME FACTORS; VIRUS REPLICATION;

EID: 84903714982     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2013.0140     Document Type: Article

References (53)

1. Agnello V, Chung RT, and Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-1495.
2. Aizaki H, Morikawa K, Fukasawa M, et al. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 2008;82:5715-5724. (Pubitemid 351822247)
3. Aly HH, Oshiumi H, Shime H, et al. Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). PLoS One 2011;6:e21284.
4. Aly HH, Qi Y, Atsuzawa K, et al. Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus. Hepatology 2009;50:689-696.
5. Aly HH, Shimotohno K, Hijikata M, and Seya T. In vitro models for analysis of the hepatitis C virus life cycle. Microbiol Immunol 2012;56:1-9.
6. Asselah T, and Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 2014;34:60-68.
7. Bare P, Massud I, Parodi C, et al. Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J Gen Virol 2005;86:1717-1727. (Pubitemid 40766884)
8. Bartosch B, Dubuisson J, and Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197; 633-642. (Pubitemid 36314658)
9. Bartosch B, Vitelli A, Granier C, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003;278:41624-41630. (Pubitemid 37310418)
10. Castet V, Fournier C, Soulier A, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002;76:8189-8199. (Pubitemid 34809073)
11. Chen Z, Zhu Y, Ren Y, et al. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS One 2011;6:e18933.
12. Donada C, Crucitti A, Donadon V, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat 1998;5:179-185. (Pubitemid 28374727)
13. Ebihara T, Shingai M, Matsumoto M, Wakita T, and Seya T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 2008;48:48-58. (Pubitemid 351975530)
14. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-805. (Pubitemid 46582027)
15. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994;88:392-394. (Pubitemid 24318191)
16. Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, and Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996;25:427-432. (Pubitemid 26345885)
17. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with Pegylated interferon and ribavirin in treatment-nai{dotless}̈ve genotype 1 hepatitis C: the randomized PILLAR Study. Hepatology 2013;58:1918-1929.
18. Harwood NE, and Batista FD. New insights into the early molecular events underlying B cell activation. Immunity 2008;28:609-619. (Pubitemid 351636250)
19. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003;100: 7271-7276. (Pubitemid 36706428)
20. Inokuchi M, Ito T, Uchikoshi M, et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 2009;627:619-627.
21. Ito M, Masumi A, Mochida K, et al. Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection. J Innate Immun 2010;2:607-617.
22. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
23. Jahan S, Khaliq S, Siddiqi MH, et al. Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol J 2011;8:522.
24. Kambara H, Fukuhara T, Shiokawa M, et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol 2012;86:1382-1393.
25. Karavattathayyil SJ, Kalkeri G, Liu HJ, et al. Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. Am J Clin Pathol 2000;113:391-398. (Pubitemid 30217387)
26. Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010;116;4926-4933.
27. Kondo Y, and Shimosegawa T. Direct effects of hepatitis C virus on the lymphoid cells. World J Gastroenterol 2013; 19:7889-7895.
28. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, and Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008;135:1322-1332.
29. Lanford RE, Chavez D, Chisari FV, and Sureau C. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 1995;69:8079-8083.
30. Laskus T, Radkowski M, Wang LF, Vargas H, and Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis 1998;178:1189-1192. (Pubitemid 28452222)
31. Lerat H, Berby F, Trabaud MA, et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996;97:845-851. (Pubitemid 26057104)
32. Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatrol 2014;60:490-499.
33. Lowe SW, and Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-495. (Pubitemid 30137934)
34. MacParland SA, Pham TN, Guy CS, and Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 2009;49:1431-1441.
35. Marukian S, Jones CT, Andrus L, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008;48:1843-1850.
36. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996;77:2604-2613. (Pubitemid 126497594)
37. McKeating JA, Zhang LQ, Logvinoff C, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol 2004;78:8496-8505. (Pubitemid 39025115)
38. Mizuochi T, Ito M, Takai K, and Yamaguchi K. Peripheral blood memory B cells are resistant to apoptosis in chronic hepatitis C patients. Virus Res 2011;155:349-351.
39. Murakami K, Kimura T, Shoji I, et al. Virological characterization of the hepatitis C virus JFH-1 strain in lymphocytic cell lines. J Gen Virol 2008;89:1587-1592.
40. Muratori L, Gibellini D, Lenzi M, et al. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood 1996;88:2768-2774. (Pubitemid 26327532)
41. Phan T, Beran RKF, Peters C, Lorenz IC, and Lindenbach BD. Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol 2009;83:8379-8395.
42. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941. (Pubitemid 28507525)
43. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-886.
44. Qu J, Zhang Q, Li Y, et al. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol 2012;13:15.
45. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-114. (Pubitemid 40066388)
46. Ramakrishnaiah V, Thumann C, Fofana I, et al. Exosomemediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A 2013; 110:13109-13113.
47. Sarhan MA, Pham TNQ, Chen AY, and Michalak TI. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol 2012;86:3723-3735.
48. Schmidt WN, Stapleton JT, LaBrecque DR, et al. Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV RNA concentrations and correlation with liver histology. Hepatology 2000;31: 737-744. (Pubitemid 30118644)
49. Schulze-Bergkamen H, Krammer P.H. Apoptosis in cancer-implications for therapy. Semin Oncol 2004;31: 90-119.
50. Seto WK, Lai CL, Fung J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010; 53:444-448.
51. Sung VM, Shimodaira S, Doughty AL, et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003;77:2134-2146. (Pubitemid 36110026)
52. Turner NC. Hepatitis C and B-cell lymphoma. Ann Oncol 2003;14:1341-1345. (Pubitemid 37185279)
53. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med 2005;11:791-796. (Pubitemid 41021213)